Merger of Upjohn and Pharmacia Company
The Upjohn Company:
The Upjohn - Pharmacia Merger
Pharmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25% by 1998.
Jan Ekberg, President and CEO of Pharmacia
Proposed Chairman of Pharmacia & Upjohn.
This is a merger that truly constitutes far more than the sum of the parts. The new company will be able to take full advantage of uniquely complementary geographic reach, product portfolio, pipeline and R&D strengths. As a result of the merger, Pharmacia &
Upjohn will have extensive financial and operating resources, market scope and earnings potential. Consequently, we fully expect the new company to achieve additional growth in expected 1996 EPS as well as acceleration of future earnings growth. Above all, Pharmacia &
Upjohn is expected to generate significantly enhanced value for shareholders.
John L. Zabriskie, Ph.D.
Chairman and CEO of Upjohn
Proposed President and CEO of Pharmacia & Upjohn
On August 20, 1995, The Upjohn Company and Pharmacia AB, two pharmaceutical companies incorporated in the U.S. and Sweden, respectively, announced that they were forming a
“merger of equals.” With combined sales of nearly $7 billion, the new company would be the ninth largest pharmaceutical company in the world. Management and major shareholders alike seemed excited by the deal. William U. Parfet, great-grandson of founder W.E. Upjohn and a company director stated, “We recognize we’re being distanced from our heritage, and that tugs at you, but this is absolutely the right thing for Upjohn to do in today’s environment, and John Zabriskie is really the
The Upjohn - Pharmacia Merger
Pharmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25% by 1998.
Jan Ekberg, President and CEO of Pharmacia
Proposed Chairman of Pharmacia & Upjohn.
This is a merger that truly constitutes far more than the sum of the parts. The new company will be able to take full advantage of uniquely complementary geographic reach, product portfolio, pipeline and R&D strengths. As a result of the merger, Pharmacia &
Upjohn will have extensive financial and operating resources, market scope and earnings potential. Consequently, we fully expect the new company to achieve additional growth in expected 1996 EPS as well as acceleration of future earnings growth. Above all, Pharmacia &
Upjohn is expected to generate significantly enhanced value for shareholders.
John L. Zabriskie, Ph.D.
Chairman and CEO of Upjohn
Proposed President and CEO of Pharmacia & Upjohn
On August 20, 1995, The Upjohn Company and Pharmacia AB, two pharmaceutical companies incorporated in the U.S. and Sweden, respectively, announced that they were forming a
“merger of equals.” With combined sales of nearly $7 billion, the new company would be the ninth largest pharmaceutical company in the world. Management and major shareholders alike seemed excited by the deal. William U. Parfet, great-grandson of founder W.E. Upjohn and a company director stated, “We recognize we’re being distanced from our heritage, and that tugs at you, but this is absolutely the right thing for Upjohn to do in today’s environment, and John Zabriskie is really the